These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 38442454

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, Schulte B, Schulte D, Franke A, Nikolaus S, Schroeder JO, Vandeputte D, Raes J, Szymczak S, Waetzig GH, Zeuner R, Schmitt-Kopplin P, Kaleta C, Schreiber S, Rosenstiel P.
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [Abstract] [Full Text] [Related]

  • 3. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP, Chaparro M.
    J Crohns Colitis; 2020 Jun 19; 14(5):694-709. PubMed ID: 31777929
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, Bewshea CM, Nice R, Lin S, Prabhudev H, Sands C, Horneffer-van der Sluis V, Lewis M, Sebastian S, Lees CW, Teare JP, Hart A, Goodhand JR, Kennedy NA, Korcsmaros T, Marchesi JR, Ahmad T, Powell N.
    EBioMedicine; 2023 Feb 19; 88():104430. PubMed ID: 36634565
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT.
    Aliment Pharmacol Ther; 2022 Jan 19; 55(1):26-48. PubMed ID: 34751954
    [Abstract] [Full Text] [Related]

  • 9. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
    Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD.
    mBio; 2018 Mar 13; 9(2):. PubMed ID: 29535202
    [Abstract] [Full Text] [Related]

  • 10. Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients.
    Čipčić Paljetak H, Barešić A, Panek M, Perić M, Matijašić M, Lojkić I, Barišić A, Vranešić Bender D, Ljubas Kelečić D, Brinar M, Kalauz M, Miličević M, Grgić D, Turk N, Karas I, Čuković-Čavka S, Krznarić Ž, Verbanac D.
    Gut Microbes; 2022 Mar 13; 14(1):2083419. PubMed ID: 35695669
    [Abstract] [Full Text] [Related]

  • 11. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission.
    Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A, Ellul P.
    Microbiol Spectr; 2022 Jun 29; 10(3):e0061622. PubMed ID: 35532243
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review.
    Recharla N, Geesala R, Shi XZ.
    Nutrients; 2023 May 11; 15(10):. PubMed ID: 37242159
    [Abstract] [Full Text] [Related]

  • 14. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ, Borman ZA, Ji J, Dubinsky MC, Ungaro RC.
    Dig Dis Sci; 2022 Jun 11; 67(6):2480-2484. PubMed ID: 34021427
    [Abstract] [Full Text] [Related]

  • 15. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA.
    Clin Gastroenterol Hepatol; 2019 Aug 11; 17(9):1655-1668.e3. PubMed ID: 30928454
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R, Moe ØK, Johnsen KM, Meyer R, Friestad J, Gundersen MD, Kileng H, Johnsen K, Florholmen JR.
    BMC Gastroenterol; 2022 Nov 17; 22(1):464. PubMed ID: 36384462
    [Abstract] [Full Text] [Related]

  • 17. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
    Imhann F, Vich Vila A, Bonder MJ, Fu J, Gevers D, Visschedijk MC, Spekhorst LM, Alberts R, Franke L, van Dullemen HM, Ter Steege RWF, Huttenhower C, Dijkstra G, Xavier RJ, Festen EAM, Wijmenga C, Zhernakova A, Weersma RK.
    Gut; 2018 Jan 17; 67(1):108-119. PubMed ID: 27802154
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease.
    Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S.
    Aliment Pharmacol Ther; 2020 Nov 17; 52(9):1453-1468. PubMed ID: 32969507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.